- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Satellos Bioscience Inc. Common Stock(MSLE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MSLE
11/13/2026: MSLE (1-star) is currently NOT-A-BUY. Pass it for now.
Satellos Bioscience is a clinical-stage biotechnology company focused on treating muscle-wasting disorders by restoring muscle stem cell polarity. Its core strength lies in the novel MyoReGenX platform, which offers a potentially differentiated oral small-molecule approach compared to standard gene therapies. While the company presents a significant growth opportunity, it faces high risks related to the early-stage nature of its pipeline, capital requirements, and intense competition from larger, more established industry players. This stock is suited for high-risk, growth-oriented investors who are comfortable with binary clinical trial outcomes. Investors should monitor progress regarding IND filings, clinical trial initiation, and potential strategic partnerships that could provide non-dilutive capital.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high potential upside for growth investors, but the speculative nature of early-stage drug development creates significant uncertainty. |
| Momentum investor | Weak fit | The stock often lacks the sustained volume and technical trend signals required to be a consistent momentum play. |
| Value investor | Weak fit | The company has no revenue and high cash burn, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay a dividend and is focused on reinvesting all capital into R&D. |
| Low-risk investor | Weak fit | The company's status as an early-stage clinical biotech entails high volatility and significant risk of capital loss. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap biotech stocks are highly sensitive to news, clinical results, and market sentiment. |
| Valuation risk | High | Determining fair value is difficult without commercial revenue or late-stage clinical data. |
| Competition risk (DMD space) | High | The company faces well-capitalized competitors with established therapeutic pipelines. |
| Business quality | Medium | The business model is highly specialized but remains unproven in human clinical settings. |
| Dividend income | Low / none | There is no expectation of income for investors. |
| Execution risk | High | Success depends entirely on the ability to translate preclinical successes into successful clinical trials. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 140.56M USD | Price to earnings Ratio - | 1Y Target Price 24.17 |
Price to earnings Ratio - | 1Y Target Price 24.17 | ||
Volume (30-day avg) 52.0K shares | Beta 1.19 | 52 Weeks Range 5.44 - 13.39 | Updated Date 11/14/2026 |
52 Weeks Range 5.44 - 13.39 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.95 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -0.99% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Research and Development | Future licensing fees, milestone payments, and potential product sales upon regulatory approval. | Currently, the company is not generating revenue and is funded through equity capital to support the discovery and development of new medicines. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 80.62M | Price to Sales(TTM) - |
Enterprise Value 80.62M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 4.75 | Shares Outstanding 21.22M | Shares Floating 18.02M |
Shares Outstanding 21.22M | Shares Floating 18.02M | ||
Percent Insiders 6.37 | Percent Institutions 50.09 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

